Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Relapsing Multiple Sclerosis
NCT01874340Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of secukinumab in multiple sclerosis (MS), sponsored by Novartis. Started Jun 2013; status: terminated.
02
Drugs
secukinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01874340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01874340.